Presentation of the Result of Medivir's Voluntary Redemption Programme

Wirtschaftsnachrichten (Symbolbild) ©unsplash.com

PR Newswire

STOCKHOLM, Mar 03, 2017

STOCKHOLM, Mar 03, 2017 /PRNewswire/ --

Medivir AB (Nasdaq Stockholm: MVIR) today announces the result of Medivir's voluntary redemption programme. The redemption programme comprised a total of 6,738,655 shares in Medivir. Upon completion of the application period, a total of 6,647,060 shares have been registered for redemption, whereof 131,589 series A shares and 6,515,471 series B shares, corresponding to an acceptance level of 98.6 per cent. In total, cash proceeds of approximately SEK 857.5 million will be distributed to the shareholders, corresponding to SEK 129 per redeemed share, to be paid around 24 March 2017.

Following completion of the redemption programme, the total number of outstanding shares in Medivir will amount to 20,318,977 shares, whereof 474,769 series A shares and 19,844,208 series B shares, and the total number of votes will amount to 24,591,898 votes.

Commission-free sale

For the commission-free sale of redemption rights, the average sales proceeds amounted to SEK 13.26 per redemption right. Payment of proceeds of the commission-free sale of redemption rights is expected to be made to the relevant shareholders around 3 March 2017.

Trading in redemption shares

Trading in redemption shares is expected to commence on 8 March 2017 and end on 15 March 2017.

ARIVA.DE Börsen-Geflüster

Kurse

MEDIVIR

0,00%

MEDIVIR AB

0,236 €

0,00%

For further information, please contact:

Ola Burmark,
CFO Medivir AB,
Mobile: +46 (0)725-480-580.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 3 March 2017.

About Medivir

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/presentation-of-the-result-of-medivir-s-voluntary-redemption-programme,c2203616

The following files are available for download:

http://mb.cision.com/Main/652/2203616/637155.pdf

Press release (PDF)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/presentation-of-the-result-of-medivirs-voluntary-redemption-programme-300417592.html

SOURCE Medivir

Mehr Nachrichten zur MEDIVIR AB Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.